Spravato has been approved since 2019 for TRD, with its label extended the following year as a rescue therapy for adults with major depressive disorder (MDD) who were at risk of self-harm or suicide.

Johnson & Johnson’s Spravato nasal spray has been approved to treat a major depressive disorder in adults who have had an inadequate response to at least two oral antidepressants, the FDA ...

Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression (TRD) too high to offer value for money, says a US cost-effectiveness body. The Institute for Clinical ...

21, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today the U.S. Food and Drug Administration (FDA) approval of a supplemental New Drug Application (sNDA) for SPRAVATO ...

The FDA granted approval to Spravato (esketamine) as the first monotherapy for adults with treatment-resistant depression, J&J said in a news release on Tuesday, Jan. 21. The decision came after a ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD ...

It's called Spravato, made by Johnson and Johnson and it works faster than standard oral antidepressants. Spravato was first approved back in 2019, but at that time, patients had to use it with an ...

Now, the Food and Drug Administration (FDA) has expanded approval for Johnson & Johnson's nasal spray, Spravato, to be used as a standalone treatment for people with severe depression who haven't ...